Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that new data show that the pivotal Phase 3 clinical SPARKLE study with the lead candidate drug Orviglance can be completed with 80 patients, with a complete patient enrollment expected in Feb-Mar 2023 and a subsequent topline readout by mid-2023.  

Press inquiries should be adressed to: